Search research articles
Contact Us
Filters
Showing results (51-60 of 92) with videos related to
Page
of 10
Sort By:
JTO Clinical and Research Reports
|
September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung Cancers
Noura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
JCO Precision Oncology
|
March 30, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced <i>ALK</i>-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers
Emily A Miao, Beow Yeap, Sameh Daher, et al.
JCO Precision Oncology
|
January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer
Justin F Gainor, Diane Tseng, Satoshi Yoda, et al.
Cancer Discovery
|
April 7, 2021
Clinical Acquired Resistance to KRAS<sup>G12C</sup> Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka, Jessica J Lin, Chendi Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
NPJ Precision Oncology
|
August 18, 2020
Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to ROS1 inhibition
Jessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 92) with videos related to
Sort By:
Page
of 10
JTO Clinical and Research Reports
|
September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung Cancers
Noura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
JCO Precision Oncology
|
March 30, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced <i>ALK</i>-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers
Emily A Miao, Beow Yeap, Sameh Daher, et al.
JCO Precision Oncology
|
January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer
Justin F Gainor, Diane Tseng, Satoshi Yoda, et al.
Cancer Discovery
|
April 7, 2021
Clinical Acquired Resistance to KRAS<sup>G12C</sup> Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka, Jessica J Lin, Chendi Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
NPJ Precision Oncology
|
August 18, 2020
Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to ROS1 inhibition
Jessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Page
of 10